Lifeward Ltd.

LFWD Nasdaq CIK: 0001607962

Company Information

Industry Orthopedic, Prosthetic & Surgical Appliances & Supplies
SIC Code 3842
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation Israel
Business Address 200 DONALD LYNCH BLVD., MARLBOROUGH, MA, 01752
Mailing Address 200 DONALD LYNCH BLVD., MARLBOROUGH, MA, 01752
Phone 15082511154
Fiscal Year End 1231
EIN 000000000

Financial Overview

FY2024 FY

$13.85M
Revenue
-$19.57M
Net Income
$11.64M
Total Liabilities

Recent SEC Filings

Form Type Date Filed Document
8-K Current report of material events February 9, 2026 View on SEC
8-K Current report of material events January 28, 2026 View on SEC
8-K Current report of material events January 13, 2026 View on SEC
8-K Current report of material events January 6, 2026 View on SEC
S-3/A Shelf registration amendment January 2, 2026 View on SEC
8-K Current report of material events December 19, 2025 View on SEC
4 Insider stock transaction report December 12, 2025 View on SEC
DEF 14A Definitive proxy statement December 1, 2025 View on SEC
10-Q Quarterly financial report November 14, 2025 View on SEC
8-K Current report of material events November 14, 2025 View on SEC

Material Events

8-K Financial Distress February 9, 2026
High Impact
  • Lifeward Ltd. secured an extension from Nasdaq to regain compliance with the minimum bid price requirement, pushing the deadline to August 3, 2026.
  • Shareholders have approved a 1-for-12 reverse stock split, which the company is considering implementing to artificially boost its share price.
View Analysis
8-K Strategy Change January 6, 2026
High Impact
  • Shareholders approved a potential reverse stock split to increase share price and meet listing requirements.
  • Shareholders also approved increasing the total number of authorized shares, providing flexibility for future fundraising.
View Analysis

Related Companies

Companies in the same industry (SIC: 3842)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.